Affimed (AFMD) Expected to Announce Quarterly Earnings on Wednesday

Affimed (NASDAQ:AFMD) is expected to be announcing its Q4 2024 earnings results before the market opens on Wednesday, June 11th. Analysts expect the company to announce earnings of ($0.62) per share and revenue of $0.14 million for the quarter.

Affimed Trading Down 34.9%

Shares of AFMD opened at $0.18 on Wednesday. The company has a quick ratio of 1.93, a current ratio of 1.93 and a debt-to-equity ratio of 0.13. Affimed has a twelve month low of $0.07 and a twelve month high of $8.95. The firm’s 50 day moving average price is $0.57 and its two-hundred day moving average price is $1.12.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on AFMD shares. Leerink Partnrs cut shares of Affimed from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 13th. Wall Street Zen assumed coverage on Affimed in a report on Monday, May 19th. They issued a “sell” rating on the stock. HC Wainwright cut Affimed from a “buy” rating to a “neutral” rating in a research note on Wednesday, May 14th. Leerink Partners restated a “market perform” rating and issued a $0.39 target price (down previously from $5.00) on shares of Affimed in a research note on Tuesday, May 13th. Finally, Wells Fargo & Company restated an “equal weight” rating and issued a $0.10 target price (down previously from $11.00) on shares of Affimed in a research note on Tuesday, May 13th. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and one has given a buy rating to the stock. Based on data from MarketBeat, Affimed currently has a consensus rating of “Hold” and a consensus target price of $7.90.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.